Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial

Patients with a history of atrial fibrillation had a 12.7 vs. 6.3 events/100 person-years rate for major adverse cardiac events during 1.6 years of follow-up.

• A history of atrial fibrillation was linked to a higher rate of major adverse cardiac events in patients with type 2 diabetes.
• Treatment with albiglutide appeared to lower the occurrence of major adverse cardiac events regardless of whether patients had a history of atrial fibrillation.
• During follow-up, 2.5% of patients experienced an atrial fibrillation event.
• Albiglutide was associated with numerically fewer atrial fibrillation events, although this difference did not reach statistical significance.

AI simplified